HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

quinoxaline-2-carboxylic acid (4- carbamoyl- 1- (3- fluorobenzyl)- 2,7- dihydroxy- 7- methyloctyl)amide

a CCR1 antagonist and NSAID; structure in first source

Also Known As:

CP 481,715; CP 481715; CP-481,715; CP-481715; CP481,715; CP481715

Networked: 6 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinoxalines: 324
      - quinoxaline-2-carboxylic acid (4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyloctyl)amide: 6

Experts

1.	Gladue, Ronald P: 4 articles (01/2010 - 10/2003)
2.	Brown, Matthew F: 2 articles (01/2010 - 10/2003)
3.	Ogborne, Kevin T: 2 articles (03/2006 - 10/2003)
4.	Shepard, Richard M: 2 articles (03/2006 - 10/2003)
5.	Tylaska, Laurie A: 2 articles (03/2006 - 10/2003)
6.	Ahn, J: 1 article (11/2014)
7.	Alley, K M: 1 article (11/2014)
8.	Bachovchin, K A: 1 article (11/2014)
9.	Fazzini, A: 1 article (11/2014)
10.	Gauntner, T D: 1 article (11/2014)

Related Diseases

1.	Rheumatoid Arthritis 10/17/2003 - "These data illustrate that CP-481,715 is a potent and selective antagonist for CCR1 with therapeutic potential for rheumatoid arthritis and other inflammatory diseases." 01/01/2007 - "Phase II studies may be warranted to see if CP-481,715 exhibits efficacy in treating inflammatory diseases such as rheumatoid arthritis, multiple sclerosis or transplant rejection." 01/01/2010 - "Over the last several years, several of these antagonists entered clinical trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD. "
2.	Multiple Sclerosis 01/01/2007 - "Phase II studies may be warranted to see if CP-481,715 exhibits efficacy in treating inflammatory diseases such as rheumatoid arthritis, multiple sclerosis or transplant rejection." 01/01/2010 - "Over the last several years, several of these antagonists entered clinical trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD. "
3.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2010 - "Over the last several years, several of these antagonists entered clinical trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD. "
4.	Inflammation (Inflammations) 03/01/2006 - "These studies illustrate the utility of hCCR1 knockin animals to assess the activity of human specific CCR1 antagonists; demonstrate the ability of the CCR1 antagonist CP-481,715 to inhibit cell infiltration, inflammation, and Th1 cytokine responses in these animals; and suggest that CP-481,715 may be useful to modulate inflammatory responses in human disease." 03/01/2006 - "In a more generalized model of inflammation, delayed-type hypersensitivity, CP-481,715 significantly inhibited footpad swelling and decreased the amount of IFN-gamma and IL-2 produced by isolated spleen cells from sensitized animals. "
5.	Multiple Myeloma 11/01/2014 - "We compared several well-studied CCR1 antagonists including AZD4818, BX471, CCX354, CP-481715, MLN-3897 and PS899877 for their ability to inhibit binding of [(125)I]-CCL3 in vitro using membranes prepared from RPMI 8226 cells, a human multiple myeloma cell line that endogenously expresses CCR1. "

Related Drugs and Biologics

1.	BX 471
2.	Cytokines
3.	AZD-4818
4.	MLN3897
5.	Interleukin-2 (IL2)